• Established by a team of AI-driven drug discovery experts formerly at BenevolentAI, Sable aims to provide scientists with richer specialist data, initially concentrating on toxicology.
• Sable offers an AI-enhanced platform that seamlessly integrates multimodal data to produce actionable insights.The London-based company raised an oversubscribed £1.5 million pre-seed funding round, led by Episode 1 Ventures with participation from Seedcamp. 
• The funding  will enable the refinement and enhancement of their core technological infrastructure, providing a solid and expansive foundation for their data capabilities.

LONDON, 6 February 2024. Sable Bio, an innovative B2B software startup changing how biotech and pharma companies evaluate drug target safety for effective decision-making, today announced the successful closure of an oversubscribed £1.5 million pre-seed funding round, led by Episode 1 Ventures supported by Seedcamp, and ex-Deepmind, now Finster AI CEO Siddhant Jayakumar.

Sable facilitates broad access to specialist biomedical data, empowering scientists across different fields to make well-informed decisions about the safety of specific drug targets.

With unforeseen toxicity as a major driver of failure in drug discovery campaigns, Sable’s approach offers substantial cost and time savings in drug development, delivering safer drugs to patients in need more rapidly.

Founded in 2023 and headquartered in London, Sable helps scientists identify and mitigate potential safety risks for drugs in development or about to enter the clinic, using a suite of state of the art techniques.

Founder Quotes:

“We are really excited, this investment will help Sable Bio redefine drug safety assessment and change the ways actionable biomedical insights are generated. Working with with leading investors Episode 1 and Seedcamp is enabling us to build an exceptional team and a platform to accelerate safer drug development for patients in need”

Josh Almond-Thynne – Co-founder

Investor Quotes:

“Target safety remains a critical hurdle in the drug discovery process, and as two rockstar scientists, Alex and Josh are uniquely positioned to solve such a complex problem. The advent of LLMs is a monumental technological shift that will help Sable Bio unlock swathes of data previously inaccessible within the scientific literature, ultimately reducing the time-to-market and costs associated with clinical trials”

Adam – Episode 1

“Taking drugs to market from discovery to development and beyond takes far too long and toxicity is a major factor adding delays or causing such processes to fail entirely. Sable is perfectly positioned to solve this problem by providing access to the right data at the right time to those who need it, leveraging LLMs to surface data that would have previously been impossible to cover fully. Alex and Josh as co-founders have the ideal blend of scientific excellence, specific domain experience and entrepreneurially drive to be building Sable and we’re delighted to have the opportunity to partner with them“

Tom – SeedCamp

The company is currently seeking to establish partnerships with biotech, pharma, and healthtech companies, as well as academic collaborations.

The funding will enable building out a stellar team of scientists and engineers, enabling the refinement and enhancement of their core technological infrastructure, providing a solid and expansive foundation for their data capabilities

---

About Sable Bio

Sable Bio is developing a unique AI-enhanced platform designed to offer pharmaceutical companies predictive safety insights, mitigating the risk of clinical trial failures. Their innovative approach involves extracting proprietary signals from structured and unstructured data sources, leveraging large language models, causal inference techniques, and extensive domain knowledge.

About Episode 1 Ventures 

Episode 1 is a leading early-stage fund investing £500k – £2m in seed and pre-seed B2B software companies across the UK. We are a team of founders, technologists and operators who have been backing and building businesses for 20+ yrs

About Seedcamp

Seedcamp is Europe’s seed fund, identifying and investing from Angel rounds to Seed in world-class founders attacking large, global markets and solving real problems using technology. The Seedcamp Nation includes over 490 startups building breakout businesses that change the way people live, interact and buy, and includes publicly listed UiPath, Wise, and unicorns Revolut, Synthesia, Sorare, Pleo, wefox, and Grover, along with fast-growing businesses such as Peppy, Sylvera, Appwrite, Ramp and Buynomics. Seedcamp fast-tracks a founder’s vision and creates value through immediate access to smart capital, a lifelong community of support, and a global network built upon more than 15 years’ experience backing exceptional talent.